Pharmaceutical Manufacturer

Now approved for treatment of visual impairment due to diabetic macular edema and macular edema secondary to retinal vein occlusion.

The Centre for Drug Research and Development and the National Research Council Canada Biotechnology Research Institute have entered into a preferred collaboration agreement to develop new antibody-based cancer therapeutics.

Thirty-year career culminated in his appointment as vice president, pharmacy at Loblaw.

Drug indicated for adjunctive treatment of seizures associated with Lennox-Gastaut syndrome.

Well over 100 reps from pharmaceutical manufacturers, pharmacy, insurers and plan sponsors examine public-policy reforms.

Economist says increasing revenues for services is an unavoidable element of 2014 Health Accord talks

First biologic agent approved for the treatment of moderately to severely active ulcerative colitis in children.

Review finds little evidence to support benefit for most medical treatments in children with autism spectrum disorders.